A biotech with plans to make an oral drug that has the same target as Humira, formerly the world’s top-selling medicine, has raised $47.5 million in a Series A. The money arrived last year, but …
Formation Bio signs deal for TYK2 drug from China’s Lynk
Since Takeda paid billions for Nimbus Therapeutics’ program in 2022, TYK2 has been one of immunology’s hottest targets. But it’s also crowded, with biotechs herding into the signs of success and interest …
UK lowers new medicine rebate scheme to 14.5% for 2026
The UK government’s drug rebate tax will fall to 14.5% for new drugs next year, down from nearly 23%, according to new details following the UK-US trade deal revealed last week. But the payment rates …
D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3
D3 Bio has secured $108 million in a Series B fundraise, with the main goal of advancing its lead drug candidate targeting KRAS-G12C into global registrational trials. The Shanghai-based biotech plans to evaluate the drug …
FDA finalizes guidance on promotional materials for biologics and biosimilars
A new guidance document issued by the FDA this week offers recommendations for how makers of prescription biosimilars and biologic reference products should approach promotional advertising and labeling for those meds.
BlossomHill gets another $84M for macrocyclic approach to EGFR
With two cancer drugs in clinical testing, BlossomHill Therapeutics has convinced investors to fuel the San Diego startup with another $84 million in its attempt to take on AstraZeneca’s EGFR inhibitor Tagrisso. CEO Jean Cui …
FDA clears first gene therapy for rare genetic disease WAS
Fondazione Telethon’s Waskyra has become the first gene therapy in the US for Wiskott-Aldrich syndrome, and the first taken to market by a non-profit.
Dissecting the difference between positive and negative brain health sentiment using X data
IntroductionHuman behavior is significantly influenced by emotions, with negative sentiments such as fear and anxiety driving various coping mechanisms, including cognitive behavioral therapy (CBT), dietary changes, and medication use. Social media platforms like X (formerly Twitter) offer valuable insights into these behaviors due to their real-time, user-generated content. While previous research has explored general sentiment […]
UK confirms lower clawback rate for NHS medicines
The UK has cut its voluntary rebate rate for new medicines supplied to the NHS to 14.5% next year, but industry says this is “only the first step.”
Antibiotic is first approval in FDA national priority scheme
FDA approves its first ‘national priority’ drug – a version of the widely used antibiotic Augmentin XR – in double-quick time.